JBIO - Jade Biosciences, Inc. News

Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target

Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maint

HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy an

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyosi

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Hal

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile

defenseworld.net

Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerage

Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcrip

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences,

Jade Biosciences: Duration Is The Real Product

Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significan

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47

Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises

Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate

Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analy

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week sub

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I

UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45

UBS analyst Michael Yee initiates coverage on Jade Biosciences (NASDAQ:JBIO) with a Buy rating an

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Un

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I

Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st

Ciena, Docusign And 3 Stocks To Watch Heading Into Thursday

Stocks to watch: CIEN, DOCU, LULU, report earnings today. MRAAF introduces world's first 100Vdc

Jade Biosciences Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I

12 Health Care Stocks Moving In Wednesday's After-Market Session

Jade Biosciences Announces Proposed Underwritten Public Offering

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I

marketbeat.com

Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunt

Why Is Jade Biosciences Stock Trading Lower On Monday?

Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best

SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, I

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Int

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE2

Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication p

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in I

SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, In

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratin

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving I

12 Health Care Stocks Moving In Friday's Intraday Session

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session